Partnership of government, academics and industry will develop new ways of studying and screening drugs for major psychiatric illnesses LA JOLLA – August 31, 2016 —The Johns Hopkins University School of Medicine and the Salk Institute for Biological Studies will co-lead a $15.4 million effort to develop new systems for quickly screening libraries of drugs for […]
NUPLAZID is the First and Only FDA-Approved Drug for this Indication An Estimated 40 Percent of Parkinson’s Disease Patients Have Psychosis SAN DIEGO–(BUSINESS WIRE)–May 31, 2016– ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today […]
First Wave of Healthcare Providers Being Trained in 55 Cities over the Next Six Weeks Probuphine Will Be Available to Patients in June 2016 PRINCETON, N.J. — May 31, 2016—Braeburn Pharmaceuticals announces plans to make Probuphine available to healthcare providers and patients in June, immediately following Food and Drug Administration (FDA) approval on May 26, […]
Expanded use and availability of medication-assisted treatment is a top priority of federal effort to combat opioid epidemic May 26, 2016 – The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in […]
Patients and Providers Have a New Option to Combat Opioid Dependence PRINCETON, N.J.—May 26, 2016—Braeburn Pharmaceuticals announces that the U.S. Food & Drug Administration (FDA) approved Probuphine, the first implant for the maintenance treatment of opioid dependence in patients who have sustained clinical stability on low-to-moderate doses of buprenorphine, specifically 8 mg or less per […]
Company Will Stay and Fight for Civil Rights and Diversity Princeton, New Jersey— May 17, 2016—Braeburn Pharmaceuticals, developer of medications for opioid addiction and other chronic neurological diseases, will proceed with plans to develop a manufacturing and research facility in Durham County, North Carolina, despite the enactment of HB2, the controversial law that overturns local […]
Princeton, New Jersey and Lund, Sweden — 11 May, 2016 — Braeburn Pharmaceuticals and Camurus today announce top line results of a multiple-dose, pivotal Phase 2 study assessing the blockade by CAM2038 of subjective opioid effects of multiple randomized hydromorphone challenges in adults with opioid use disorder. A key objective of medication-assisted treatment for opioid […]
SAN DIEGO–(BUSINESS WIRE)–Mar. 29, 2016– ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits […]
Advisory Committee Meeting Scheduled for March 29, 2016 SAN DIEGO–(BUSINESS WIRE)–Jan. 29, 2016– ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug […]
Once-Daily, Oral Product Candidate Showed Efficacy Equivalent to Olanzapine With Clinically Meaningful and Statistically Significant Lower Weight Gain in 300-Patient Study Company Plans to Initiate Pivotal Development Program in 2015 DUBLIN–(BUSINESS WIRE)–Jan. 7, 2015– Alkermes plc (NASDAQ: ALKS) today announced positive topline results from the 12-week, randomized, double-blind, active-controlled, dose-ranging stage of a phase 2 […]